ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "mycophenolate mofetil and systemic lupus erythematosus (SLE)"

  • Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting

    Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?

    Gabriela Munhoz1, Maira Lacerda1, Michelle Lopes1, Eduardo Ferreira Borba1, Luciana Seguro2 and Eloisa Bonfa3, 1Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
  • Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting

    A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis

    Astrid Baumann1, Angela Pakozdi2, Andrea Cove-Smith2, Debasish Pyne2, Michael Sheaff1 and Ravindra Rajakariar2, 1Barts Lupus Centre, London, United Kingdom, 2Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
  • Abstract Number: 1824 • 2016 ACR/ARHP Annual Meeting

    Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients

    Samantha Slight-Webb1, Rufei Lu2, Krista M. Bean1, Holden T. Maecker3, Paul J. Utz4, Joel M. Guthridge5 and Judith A. James6, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 4Medicine, Stanford University School of Medicine, Stanford, CA, 5Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose:  The management of systemic lupus erythematosus (SLE) is complicated by a heterogeneous clinical presentation. Currently, mycophenolate mofetil (MMF) is a commonly used medication to…
  • Abstract Number: 740 • 2016 ACR/ARHP Annual Meeting

    Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment

    Maryam Ghaderi-Yeganeh1, Ann Biehl2, Zerai G. Manna3, Alice Fike4 and Sarfaraz Hasni3, 1National Institutes of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose:  Lack of adherence to treatment recommendations is a serious confounder to assessment of treatment efficacy for systemic lupus erythematosus (SLE). Estimates of nonadherence with…
  • Abstract Number: 724 • 2015 ACR/ARHP Annual Meeting

    Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus.  an Observational Cohort Study

    Konstantinos Tselios1, Dafna Gladman2, Jiandong Su2 and Murray Urowitz2,3, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Mycophenolate mofetil (MMF), along with corticosteroids, is considered as the standard of care in lupus nephritis (LN); however, its efficacy in extra-renal manifestations of…
  • Abstract Number: 2937 • 2015 ACR/ARHP Annual Meeting

    Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis

    J. Madison Hyer1, Bethany Wolf1, Jim Oates2, Gary S. Gilkeson3 and Diane L. Kamen2, 1Public Health Sciences, Medical University of South Carolina, Charleston, SC, 2Medicine, Medical University of South Carolina, Charleston, SC, 3Department of Rheumatology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…
  • Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting

    Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus

    Ananta Subedi1, Hong Fang2 and Michelle Petri2, 1Good Samaritan Hospital, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology